The Medical Letter on Drugs and Therapeutics
Brivaracetam (Briviact) for Epilepsy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Brivaracetam (Briviact – UCB), an analog of levetiracetam (Keppra, and others), has been approved by the FDA for adjunctive treatment of partial-onset seizures in patients ≥16 years old. New drugs for epilepsy are often approved initially only as adjunctive treatment for partial seizures.1

MECHANISM OF ACTION — Brivaracetam binds selectively to synaptic vesicle protein 2A (SV2A) in the brain, modulating neurotransmitter release into the synapse. Brivaracetam has a 10- to 30-fold higher affinity for SV2A than levetiracetam. It is also a partial antagonist on neuronal voltage-gated sodium channels. In animal models, brivaracetam had higher brain permeability and a more rapid onset of action than levetiracetam.2

CLINICAL STUDIES — Approval was based on the results of three ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Brivaracetam (Briviact) for Epilepsy
Article code: 1499d
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian